newwin
Luciann Nguyen
Settings
← Accounts
academic

Georgetown University

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Georgetown University

New trial — NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

New trialNCT05661201
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT05661201 posted by Georgetown University: "NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 186 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT05661201
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
phase 1
—